TheraVet Announces the Appointment of a Chief Financial Officer to Reinforce Its Global Financing and Cost Control Strategy
25 Oktober 2023 - 7:30AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets, today
announced the appointment of Rodolphe Lebrun as Chief Financial
Officer.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
stated: "We are delighted to welcome Rodolphe as Chief Financial
Officer. His profile, marked by strong financial and engineering
skills, is fully in line with the DNA of our Company. Rodolphe
already boasts solid experience, whether as a consultant, sales
manager or CFO, enabling him to fully grasp the challenges of the
biotech world. His expertise will be a key asset in pursuing and
strengthening our global financing and cost control
strategy."
Since 2016, Rodolphe acts as a strategic advisor to small and
large biotech and medtech companies on their financing, business
development and M&A activities. Before joining TheraVet,
Rodolphe Lebrun held the position of CFO at Graftys, an
orthobiology company specialized in the development, manufacture
and marketing of calcium phosphate-based synthetic bone
substitutes, during the year 2020, marked by the onset of the
Covid-19 pandemic. In this position, he was involved through active
cost management and the implementation of non-dilutive financing,
enabling the company to successfully navigate in this uncertain
period. Prior to this, he was for over 2 years Director of KPMG
Belgium's Life Sciences Practice, paying particular attention to
R&D-related topics as well as marketing and operational
strategy. Between 2014 and 2016, he worked for the biotech company
AbbVie as Customer Excellence Director and member of its Executive
Committee for Belgium and Luxembourg. Prior to this, Rodolphe spent
almost 5 years with McKinsey & Company, where he was focused on
defining operational strategy and leading operational excellence
transformations in major pharmaceutical and medtech groups, as well
as hospitals.
Rodolphe is a graduate of the Faculté Polytechnique de Mons, the
Institut Supérieur de l'Aéronautique et de l'Espace (ISAE Toulouse)
and the Solvay Brussels School of Economics and Management.
Rodolphe's role in TheraVet will be to optimize the Company's
financial structure to ensure rigorous allocation of financial
resources, and to implement and execute the Company's financial
strategy. He will also be responsible for pursuing and
strengthening the Company's cost control policy, and for managing
the Company's cash flow on a day-to-day basis.
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024445145/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
TheraVet (EU:ALVET)
Historical Stock Chart
Von Mai 2023 bis Mai 2024